{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:49:58Z","timestamp":1793332198752,"version":"4.5.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","aaojournal.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.ophtha.2017.01.021","type":"journal-article","created":{"date-parts":[[2017,2,23]],"date-time":"2017-02-23T12:17:45Z","timestamp":1487852265000},"page":"757-767","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":114,"title":["Slow-Release Dexamethasone in Proliferative Vitreoretinopathy"],"prefix":"10.1016","volume":"124","author":[{"given":"Philip J.","family":"Banerjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Quartilho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0935-3713","authenticated-orcid":false,"given":"Catey","family":"Bunce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tapiwa M.","family":"Zvobgo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Charteris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2017.01.021_bib1","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1136\/bjo.79.10.953","article-title":"Proliferative vitreoretinopathy: pathobiology, surgical management, and adjunctive treatment","volume":"79","author":"Charteris","year":"1995","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.01.021_bib2","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/sj.eye.6700194","article-title":"Proliferative vitreoretinopathy-developments in adjunctive treatment and retinal pathology","volume":"16","author":"Charteris","year":"2002","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.ophtha.2017.01.021_bib3","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1097\/00006982-200412000-00007","article-title":"Resources involved in managing retinal detachment complicated by proliferative vitreoretinopathy","volume":"24","author":"Patel","year":"2004","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2017.01.021_bib4","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S0002-9394(98)00115-9","article-title":"Adjunctive daunorubicin in the treatment of proliferative vitreoretinopathy: results of a multicenter clinical trial","volume":"126","author":"Wiedemann","year":"1998","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.01.021_bib5","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/S0161-6420(84)34318-4","article-title":"5-fluorouracil: new applications in complicated retinal detachment for an established antimetabolite","volume":"91","author":"Blumenkranz","year":"1984","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2017.01.021_bib6","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/S0161-6420(01)00589-9","article-title":"Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy: results from a randomized, double-blind, controlled clinical trial","volume":"108","author":"Asaria","year":"2001","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2017.01.021_bib7","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1016\/j.ophtha.2004.05.036","article-title":"A\u00a0randomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in management of established proliferative vitreoretinopathy","volume":"111","author":"Charteris","year":"2004","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2017.01.021_bib8","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.ophtha.2006.08.042","article-title":"Randomized controlled trial of combined 5-Fluorouracil and low-molecular-weight heparin in the management of unselected rhegmatogenous retinal detachments undergoing primary vitrectomy","volume":"114","author":"Wickham","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2017.01.021_bib9","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/S0161-6420(95)31007-X","article-title":"The effect of oral 13-cis-retinoic acid on retinal redetachment after surgical repair in eyes with proliferative vitreoretinopathy","volume":"102","author":"Fekrat","year":"1995","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2017.01.021_bib10","first-page":"268","article-title":"Proliferative vitreoretinopathy: does oral low-dose colchicine have an inhibitory effect? A controlled study in humans","volume":"20","author":"Berman","year":"1989","journal-title":"Ophthalmic Surg"},{"key":"10.1016\/j.ophtha.2017.01.021_bib11","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/BF00184007","article-title":"Radiation therapy in proliferative vitreoretinopathy. A prospective randomized study","volume":"232","author":"Binder","year":"1994","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.01.021_bib12","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1136\/bjophthalmol-2015-307347","article-title":"Triamcinolone during pars plana vitrectomy for open globe trauma; a pilot randomised controlled clinical trial","volume":"100","author":"Banerjee","year":"2016","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.01.021_bib13","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/S0002-9394(14)75196-7","article-title":"Treatment of intraocular proliferation with intravitreal injection of triamcinolone acetonide","volume":"90","author":"Tano","year":"1980","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.01.021_bib14","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/0002-9394(81)90171-9","article-title":"Glucocorticosteroid inhibition of intraocular proliferation after injury","volume":"91","author":"Tano","year":"1981","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.01.021_bib15","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/00006982-199701000-00009","article-title":"Therapeutic effect of periocular corticosteroids in experimental proliferative vitreoretinopathy","volume":"17","author":"Rubsamen","year":"1997","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2017.01.021_bib16","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1167\/iovs.06-0145","article-title":"Long-term retinal toxicity of intravitreal commercially available preserved triamcinolone acetonide (Kenalog) in rabbit eyes","volume":"48","author":"Albini","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2017.01.021_bib17","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1136\/bjo.84.9.1064","article-title":"Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative vitreoretinopathy","volume":"84","author":"Jonas","year":"2000","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.01.021_bib18","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/BF00231411","article-title":"Postoperative retinal fibrosis\u2013a controlled clinical study of systemic steroid therapy","volume":"219","author":"Koerner","year":"1982","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.01.021_bib19","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1007\/BF00184858","article-title":"Does the presence of heparin and dexamethasone in the vitrectomy infusate reduce reproliferation in proliferative vitreoretinopathy?","volume":"234","author":"Williams","year":"1996","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.01.021_bib20","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/S0008-4182(05)80052-3","article-title":"Intravitreal triamcinolone for treatment of complicated proliferative diabetic retinopathy and proliferative vitreoretinopathy","volume":"40","author":"Munir","year":"2005","journal-title":"Can J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.01.021_bib21","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3928\/15428877-20070901-02","article-title":"Triamcinolone acetonide as an adjuvant in the surgical treatment of retinal detachment with proliferative vitreoretinopathy","volume":"38","author":"Cheema","year":"2007","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"10.1016\/j.ophtha.2017.01.021_bib22","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1186\/1745-6215-14-358","article-title":"Ozurdex (a slow-release dexamethasone implant) in proliferative vitreoretinopathy: study protocol for a randomised controlled trial","volume":"14","author":"Banerjee","year":"2013","journal-title":"Trials"},{"key":"10.1016\/j.ophtha.2017.01.021_bib23","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0002-9394(14)76695-4","article-title":"An updated classification of retinal detachment with proliferative vitreoretinopathy","volume":"112","author":"Machemer","year":"1991","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.01.021_bib24","series-title":"Ozurdex Summary of Product Characteristics","year":"2015"},{"key":"10.1016\/j.ophtha.2017.01.021_bib25","series-title":"Statistical Methods for Rates and Proportions","author":"Fleiss","year":"1981"},{"key":"10.1016\/j.ophtha.2017.01.021_bib26","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s12325-011-0019-z","article-title":"The dexamethasone drug delivery system: indications and evidence","volume":"28","author":"London","year":"2011","journal-title":"Adv Ther"},{"key":"10.1016\/j.ophtha.2017.01.021_bib27","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1001\/archopht.1992.01080140115038","article-title":"Evaluation of the retinal toxicity and pharmacokinetics of dexamethasone after intravitreal injection","volume":"110","author":"Kwak","year":"1992","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.01.021_bib28","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1001\/archopht.1974.01010010155016","article-title":"Intravitreal injection of dexamethasone. Treatment of experimentally induced endophthalmitis","volume":"92","author":"Graham","year":"1974","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.01.021_bib29","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1167\/iovs.10-5285","article-title":"Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant","volume":"52","author":"Chang-Lin","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2017.01.021_bib30","doi-asserted-by":"crossref","first-page":"4605","DOI":"10.1167\/iovs.10-6387","article-title":"Pharmacokinetics of a sustained-release dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes","volume":"52","author":"Chang-Lin","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2017.01.021_bib31","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.ophtha.2010.03.032","article-title":"Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion","volume":"117","author":"Haller","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2017.01.021_bib32","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1001\/archophthalmol.2010.339","article-title":"Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis","volume":"129","author":"Lowder","year":"2011","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.01.021_bib33","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1016\/j.ophtha.2014.04.024","article-title":"Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema","volume":"121","author":"Boyer","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2017.01.021_bib34","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.ophtha.2008.05.016","article-title":"Triamcinolone acetonide in silicone-filled eyes as adjunctive treatment for proliferative vitreoretinopathy: a randomized clinical trial","volume":"115","author":"Ahmadieh","year":"2008","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2017.01.021_bib35","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s00417-011-1919-y","article-title":"Systemic corticosteroids reduce the risk of cellophane membranes after retinal detachment surgery: a prospective randomized placebo-controlled double-blind clinical trial","volume":"250","author":"Koerner","year":"2012","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.01.021_bib36","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.ajo.2008.05.002","article-title":"Effect of oral 13-cis-retinoic acid treatment on postoperative clinical outcome of eyes with proliferative vitreoretinopathy","volume":"146","author":"Chang","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.01.021_bib37","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1097\/IAE.0b013e318206d18c","article-title":"Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients","volume":"31","author":"Boyer","year":"2011","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2017.01.021_bib38","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1097\/IAE.0b013e31827e247b","article-title":"Dexamethasone intravitreal implant for treatment of uveitic persistent cystoid macular edema in vitrectomized patients","volume":"33","author":"Adan","year":"2013","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2017.01.021_bib39","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1159\/000336273","article-title":"Resolution of persistent cystoid macular edema due to central retinal vein occlusion in a vitrectomized eye following intravitreal implant of dexamethasone 0.7 mg","volume":"3","author":"Reibaldi","year":"2012","journal-title":"Case Rep Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.01.021_bib40","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3109\/15569527.2014.951450","article-title":"Post-operative refractory cystoid macular edema in a vitrectomized eye treated with slow-release dexamethasone implant (Ozurdex)","volume":"34","author":"Georgalas","year":"2015","journal-title":"Cutan Ocul Toxicol"},{"key":"10.1016\/j.ophtha.2017.01.021_bib41","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1001\/archopht.123.12.1651","article-title":"Analysis of the macula with optical coherence tomography after successful surgery for proliferative vitreoretinopathy","volume":"123","author":"Benson","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.01.021_bib42","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1167\/iovs.03-0518","article-title":"Glial remodeling and neural plasticity in human retinal detachment with proliferative vitreoretinopathy","volume":"46","author":"Sethi","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2017.01.021_bib43","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.ophtha.2008.10.001","article-title":"Foveal microstructure and visual acuity after retinal detachment repair: imaging analysis by Fourier-domain optical coherence tomography","volume":"116","author":"Wakabayashi","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2017.01.021_bib44","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ajo.2011.06.010","article-title":"Anatomical and functional macular changes after rhegmatogenous retinal detachment with macula off","volume":"153","author":"Delolme","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.01.021_bib45","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ajo.2009.01.018","article-title":"Outer nuclear layer thickness at the fovea determines visual outcomes in resolved central serous chorioretinopathy","volume":"148","author":"Matsumoto","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.01.021_bib46","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3928\/23258160-20150422-17","article-title":"Microstructural retinal findings by spectral-domain optical coherence tomography after vitrectomy repair of rhegmatogenous retinal detachments","volume":"46","author":"Kumar","year":"2015","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.ophtha.2017.01.021_bib47","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1186\/s13063-016-1464-4","volume":"17","author":"Lo","year":"2016","journal-title":"Trials"},{"key":"10.1016\/j.ophtha.2017.01.021_bib48","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1186\/s13063-016-1445-7","volume":"17","author":"Banerjee","year":"2016","journal-title":"Trials"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642016311848?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642016311848?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,2]],"date-time":"2020-10-02T19:15:09Z","timestamp":1601666109000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642016311848"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S0161642016311848"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2017.01.021","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Slow-Release Dexamethasone in Proliferative Vitreoretinopathy","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2017.01.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}